177488-99-2

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 58315-37-0 1-(2-methoxy-5-nitrophenyl)piperazine 

Downstream Products

• 148546-91-2 tert-butyl 4-(5-amino-2-methoxyphenyl)piperazine-1-carboxylate 
• 209481-82-3 tert-butyl 4-(5-{[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]amino}-2-methoxyphenyl)piperazine-1-carboxylate 
• 1608469-58-4 tert-butyl 4-(5-iodo-2-methoxyphenyl)piperazine-1-carboxylate 
• 1608469-59-5 tert-butyl 4-(5-(3-(difluoromethoxy)phenylsulfonyl)-2-methoxyphenyl)piperazine-1-carboxylate 
• 1608469-56-2 1-(5-(3-(difluoromethoxy)phenylsulfonyl)-2-methoxyphenyl)-4-([³H]methyl)-piperazine 
• 1608469-50-6 1-(5-(3-(difluoromethoxy)phenylsulfonyl)-2-methoxyphenyl)-4-(2-[¹⁸F]fluoroethyl)piperazine 

Relevant academic research and scientific papers

BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR

The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R1 is hydrogen or methyl R2 is hydrogen or methyl R3 hydrogen, fluorine C1-C2 alkoxy or fluorinated C1-C2 alkoxy; R4 is hydrogen, C1-C4 alkyl or fluorinated C1-C4 alkyl; R5 is hydrogen, fluorine, C1-C2 alkyl fluorinated C1-C2 alkyl C1-C2 alkoxy or fluorinated C1-C2 alkoxy; and R6 is hydrogen, fluorine or chlorine.